Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plan B One-Step Goes OTC, With Three-Year Exclusivity, Lower Age Limit

This article was originally published in The Tan Sheet

Executive Summary

FDA approved Plan B One-Step to be sold in some OTC venues to women 15 and older, lowering the age restriction and moving the product out from behind pharmacy counters. Teva Women’s Health gets three years of exclusivity for the product, based on studies of label comprehension among women as young as 15.

You may also be interested in...



Teva Plan B OTC Application Fails Political Test After Clearing FDA Hurdle

HHS Secretary Sebelius says Teva must show more evidence of how young adolescent females would use Plan B One-Step as an OTC. But obtaining such clinical data for the emergency contraceptive – in excess of what FDA already needed to approve it – appears nearly impossible, experts say.

OTC Decisions November-December: GSK Labels For Nexium Promotion, Voltaren 2-Pack Approved

Approvals by FDA also include revised container and consumer information labeling for J&J's Men’s Rogaine to align with labeling for Women’s Rogaine;  bonus-pack labeling for Bayer AG’s Aleve; and 

J&J CEO: COVID-19 ‘Demonstrated Importance of Self-Care Overall’

During JP Morgan conference, Alex Gorsky suggests responding to pandemic is changing health care, including businesses providing pharmaceuticals, medical technologies, nutritionals and other necessary products.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel